Cisplatin nephrotoxicity: molecular mechanisms.
暂无分享,去创建一个
[1] W. Zeller,et al. Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells , 1995, Cell Biology and Toxicology.
[2] L. Rybak,et al. Protection by ebselen against cisplatin-induced nephrotoxicity: Antioxidant system , 2004, Molecular and Cellular Biochemistry.
[3] P. Mistry,et al. Intracellular metabolites of cisplatin in the rat kidney , 2004, Cancer Chemotherapy and Pharmacology.
[4] R. Mayer,et al. Inhibition of cisplatin-induced nephrotoxicity in rats by buthionine sulfoximine, a glutathione synthesis inhibitor , 2004, Cancer Chemotherapy and Pharmacology.
[5] Y. Iwamoto,et al. Sodium thiosulfate inhibits cis-diamminedichloroplatinum (II) activity , 2004, Cancer Chemotherapy and Pharmacology.
[6] J. Marto,et al. High pressure liquid chromatography and mass spectrometry characterization of the nephrotoxic biotransformation products of Cisplatin. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[7] T. Sugiyama,et al. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a chemoresistance marker in human oral squamous cell carcinoma treated with cisplatin. , 2003, Oral oncology.
[8] T. Ninomiya,et al. Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. , 2003, Kidney international.
[9] D. Townsend,et al. Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. , 2003, Journal of the American Society of Nephrology : JASN.
[10] W. Curran. New Chemotherapeutic Agents: Update of Major Chemoradiation Trials in Solid Tumors , 2002, Oncology.
[11] Myriam Rochdi,et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. , 2002, Cancer research.
[12] G. Nowak. Protein Kinase C- (cid:1) and ERK1/2 Mediate Mitochondrial Dysfunction, Decreases in Active Na (cid:2) Transport, and Cisplatin-induced Apoptosis in Renal Cells* , 2022 .
[13] S. Howell,et al. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. , 2002, Molecular pharmacology.
[14] I. Herskowitz,et al. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[15] G. Ramesh,et al. TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity , 2002 .
[16] K. Utsumi,et al. L-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. , 2002, Archives of biochemistry and biophysics.
[17] Arthur J. L. Cooper,et al. Toxic, halogenated cysteine S-conjugates and targeting of mitochondrial enzymes of energy metabolism. , 2002, Biochemical pharmacology.
[18] R. Schnellmann,et al. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. , 2002, The Journal of pharmacology and experimental therapeutics.
[19] P. Devarajan,et al. Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. , 2002, Journal of the American Society of Nephrology : JASN.
[20] Jerry Goodisman,et al. Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[21] D. Townsend,et al. Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice. , 2002, The Journal of pharmacology and experimental therapeutics.
[22] R. H. Lee,et al. Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells. , 2001, Biochemical pharmacology.
[23] D. Townsend,et al. (cid:2) -Glutamyl Transpeptidase-Deficient Mice Are Resistant to the Nephrotoxic Effects of Cisplatin , 2001 .
[24] M. Fukumoto,et al. Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines. , 2001, Oncology reports.
[25] Sudhir V. Shah,et al. Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. , 2001, Kidney international.
[26] W. Dekant. Chemical-induced nephrotoxicity mediated by glutathione S-conjugate formation. , 2001, Toxicology letters.
[27] R E Stoll,et al. Assessment of cisplatin-induced nephrotoxicity by microarray technology. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.
[28] B. van de Water,et al. Suppression of Chemically Induced Apoptosis but Not Necrosis of Renal Proximal Tubular Epithelial (LLC-PK1) Cells by Focal Adhesion Kinase (FAK) , 2001, The Journal of Biological Chemistry.
[29] A. Hishida,et al. Role of the increase in p21 in cisplatin-induced acute renal failure in rats. , 2001, Journal of the American Society of Nephrology : JASN.
[30] M. Inoue,et al. Targeting superoxide dismutase to renal proximal tubule cells inhibits mitochondrial injury and renal dysfunction inuduced by cisplatin. , 2001, Archives of biochemistry and biophysics.
[31] J. Stevens,et al. Role of mitochondrial dysfunction in S-(1,2-dichlorovinyl)-l-cysteine-induced apoptosis. , 2001, Toxicology and applied pharmacology.
[32] A. Langerak. Chemotherapy Regimens and Cancer Care , 2001 .
[33] Seth M. Cohen,et al. Cisplatin: from DNA damage to cancer chemotherapy. , 2001, Progress in nucleic acid research and molecular biology.
[34] S. Korsmeyer,et al. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c , 2000, Cell Death and Differentiation.
[35] G. Kroemer,et al. Mitochondria--the Death Signal Integrators , 2000, Science.
[36] B. van de Water,et al. Cleavage of the Actin-capping Protein α-Adducin at Asp-Asp-Ser-Asp633-Ala by Caspase-3 Is Preceded by Its Phosphorylation on Serine 726 in Cisplatin-induced Apoptosis of Renal Epithelial Cells* , 2000, The Journal of Biological Chemistry.
[37] M. Kool,et al. A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.
[38] M. V. Heiden,et al. Redox regulation of p53 during hypoxia , 2000, Oncogene.
[39] M. Mariggiò,et al. Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role? , 2000, The Journal of pharmacology and experimental therapeutics.
[40] L. Truong,et al. Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. , 2000, American journal of physiology. Renal physiology.
[41] G. Kaushal,et al. Apoptotic mechanisms in acute renal failure. , 2000, The American journal of medicine.
[42] A. Hishida,et al. Role of apoptosis in uranyl acetate-induced acute renal failure and acquired resistance to uranyl acetate. , 2000, Kidney international.
[43] N. Farrell,et al. Platinum-Based Drugs in Cancer Therapy , 2000, Cancer Drug Discovery and Development.
[44] Gerard I. Evan,et al. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant , 2000, Nature Cell Biology.
[45] M. Mutoh,et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. , 2000, Cancer research.
[46] M. Okuda,et al. Role of apoptosis in cisplatin-induced toxicity in the renal epithelial cell line LLC-PK1. Implication of the functions of apical membranes. , 2000, Biochemical pharmacology.
[47] S. Howell,et al. How Does Cisplatin Kill Cells , 2000 .
[48] M. McKeage. Clinical Toxicology of Platinum-Based Cancer Chemotherapeutic Agents , 2000 .
[49] F. Hamada,et al. Prevention of cisplatin-induced nephrotoxicity by methimazole. , 2000, Pharmacological research.
[50] A. Hishida,et al. Attenuation of cisplatin-induced acute renal failure is associated with less apoptotic cell death. , 1999, The Journal of laboratory and clinical medicine.
[51] J. Stevens,et al. The roles of caspase-3 and bcl-2 in chemically-induced apoptosis but not necrosis of renal epithelial cells , 1999, Oncogene.
[52] T. Burns,et al. The p53 pathway and apoptosis , 1999, Journal of cellular physiology.
[53] S. Fulda,et al. Cytotoxic drugs and the CD95 pathway , 1999, Leukemia.
[54] A. Lau,et al. Apoptosis induced by cisplatin nephrotoxic injury. , 1999, Kidney international.
[55] M W Parker,et al. The ligandin (non-substrate) binding site of human Pi class glutathione transferase is located in the electrophile binding site (H-site). , 1999, Journal of molecular biology.
[56] M. del Río,et al. Partial ATP depletion induces Fas- and caspase-mediated apoptosis in MDCK cells. , 1999, American journal of physiology. Renal physiology.
[57] M. Razzaque,et al. Cisplatin-induced apoptosis in human proximal tubular epithelial cells is associated with the activation of the Fas/Fas ligand system , 1999, Histochemistry and Cell Biology.
[58] Y. Sugiyama,et al. Differences in Substrate Specificity among Glutathione Conjugates (GS‐X) Pump Family Members: Comparison between Multidrug Resistance‐associated Protein and a Novel Transporter Expressed on a Cisplatin‐resistant Cell Line (KCP‐4) , 1999, Japanese journal of cancer research : Gann.
[59] D. Townsend,et al. Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo. , 1999, Carcinogenesis.
[60] A. Lichtenstein,et al. Differential effects of cisplatin in proximal and distal renal tubule epithelial cell lines , 1999, British Journal of Cancer.
[61] 利仁 福岡. Distinct Interleukin-1 β-Converting Enzyme Family Proteases Mediate Cisplatin- and Staurosporine-induced Apoptosis of Mouse Proximal Tubule Cells , 1998 .
[62] J. Weinberg,et al. Mechanisms of cell death in hypoxia/reoxygenation injury , 1998, Oncogene.
[63] D. Israeli,et al. p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.
[64] Masahiro Higuchi,et al. Regulation of reactive oxygen species-induced apoptosis and necrosis by caspase 3-like proteases , 1998, Oncogene.
[65] J. Lindsay,et al. Mitochondrial stress protein recognition of inactivated dehydrogenases during mammalian cell death. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[66] R. Perez,et al. Cellular and molecular determinants of cisplatin resistance. , 1998, European journal of cancer.
[67] V. Dixit,et al. Death receptors: signaling and modulation. , 1998, Science.
[68] S. Cory,et al. The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.
[69] Y. Lazebnik,et al. Caspases: enemies within. , 1998, Science.
[70] Xiaodong Wang,et al. Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.
[71] G. Mulder,et al. Cisplatin effects on F-actin and matrix proteins precede renal tubular cell detachment and apoptosis in vitro , 1998, Cell Death and Differentiation.
[72] A. Hishida,et al. The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. , 1998, The Journal of laboratory and clinical medicine.
[73] L. Dworkin,et al. Hepatocyte growth factor protects renal epithelial cells from apoptotic cell death. , 1998, Biochemical and biophysical research communications.
[74] B. Trock,et al. Association between expression of glutathione-associated enzymes and response to platinum-based chemotherapy in head and neck cancer. , 1998, Chemico-biological interactions.
[75] K. Schulze-Osthoff,et al. Role of Reactive Oxygen Intermediates in Activation-induced CD95 (APO-1/Fas) Ligand Expression* , 1998, The Journal of Biological Chemistry.
[76] Y. Nakanishi,et al. Induction of apoptosis in ischemia-reperfusion model of mouse kidney: possible involvement of Fas. , 1998, Journal of the American Society of Nephrology : JASN.
[77] S. Wright,et al. Na-dependent transport of S-(1,2-dichlorovinyl)-L-cysteine by renal brush-border membrane vesicles. , 1998, The Journal of pharmacology and experimental therapeutics.
[78] J. Megyesi,et al. Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. , 1998, The Journal of clinical investigation.
[79] Y. Minagawa,et al. Glutathione concentration may be a useful predictor of response to second‐line chemotherapy in patients with ovarian cancer , 1998, Cancer.
[80] X. Chen,et al. [The expression of glutathione S-transferase pi in human ovarian cancer as an indicator of resistance to chemotherapy]. , 1998, Zhonghua fu chan ke za zhi.
[81] W. van der Vijgh,et al. Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice. , 1998, European journal of cancer.
[82] H. Endou,et al. Involvement of macromolecule synthesis, endonuclease activation and c-fos expression in cisplatin-induced apoptosis of mouse proximal tubule cells. , 1998, Toxicology letters.
[83] W. Dekant,et al. Glutathione-dependent bioactivation of haloalkenes. , 1998, Annual review of pharmacology and toxicology.
[84] D. Putt,et al. Glutathione conjugation of trichloroethylene in rats and mice: sex-, species-, and tissue-dependent differences. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[85] K. Kinzler,et al. 14-3-3σ Is a p53-Regulated Inhibitor of G2/M Progression , 1997 .
[86] John Calvin Reed,et al. Cytochrome c: Can't Live with It—Can't Live without It , 1997, Cell.
[87] A. V. D. Van Der Zee,et al. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents , 1997, Oncogene.
[88] R. Prescott,et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[89] Sudhir V. Shah,et al. Oxidant mechanisms in toxic acute renal failure. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[90] Y. Minagawa,et al. Glutathione S‐transferase‐π expression and glutathione concentration in ovarian carcinoma before and after chemotherapy , 1997 .
[91] B. van de Water,et al. Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. , 1997, The Journal of pharmacology and experimental therapeutics.
[92] H. Endou,et al. Cisplatin-induced apoptosis of immortalized mouse proximal tubule cells is mediated by interleukin-1β converting enzyme (ICE) family of proteases but inhibited by overexpression of Bcl-2 , 1997, Archives of Toxicology.
[93] J. Megyesi,et al. The p53-independent activation of transcription of p21 WAF1/CIP1/SDI1 after acute renal failure. , 1996, The American journal of physiology.
[94] H. Frierson,et al. Immunohistochemical detection of gamma-glutamyl transpeptidase in normal human tissue. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[95] M. Esposito,et al. Effect of the antiarrhythmic drug procainamide on the toxicity and antitumor activity of cis-diamminedichloroplatinum(II). , 1996, Toxicology and applied pharmacology.
[96] T. Takayama,et al. Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. , 1996, Cancer research.
[97] T. Ishikawa,et al. Coordinated Induction of MRP/GS-X Pump and γ-Glutamylcysteine Synthetase by Heavy Metals in Human Leukemia Cells* , 1996, The Journal of Biological Chemistry.
[98] W. Lieberthal,et al. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. , 1996, The American journal of physiology.
[99] J. Brisson,et al. Markers of chemoresistance in ovarian carcinomas: an immunohistochemical study of 86 cases. , 1996, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[100] J. Morin,et al. The cellular toxicity of two antitumoural agents derived from platinum, cisplatinum versus oxaliplatinum, on cultures of tubular proximal cells. , 1996, Drugs under experimental and clinical research.
[101] J. Megyesi,et al. DNA synthesis is dissociated from the immediate-early gene response in the post-ischemic kidney. , 1995, Kidney international.
[102] S. Lippard,et al. Cisplatin and DNA repair in cancer chemotherapy. , 1995, Trends in biochemical sciences.
[103] R. Schlapbach,et al. Oxidants in mitochondria: from physiology to diseases. , 1995, Biochimica et biophysica acta.
[104] M. W. Anders. Mitochondrial bioactivation of cysteine S-conjugates and 4-thiaalkanoates: implications for mitochondrial dysfunction and mitochondrial diseases. , 1995, Biochimica et biophysica acta.
[105] P. Teesdale-Spittle,et al. The C-S lysis of L-cysteine conjugates by aspartate and alanine aminotransferase enzymes , 1995, Human & experimental toxicology.
[106] John Calvin Reed,et al. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.
[107] H. Furumoto,et al. Expression of glutathione S‐transferase‐π in human ovarian cancer as an indicator of resistance to chemotherapy , 1994 .
[108] P. Taylor,et al. Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity. , 1994, Cancer research.
[109] Inhibition of cisplatin toxicity without decreasing antitumor efficacy. Use of a dithiocarbamate. , 1994, Archives of otolaryngology--head & neck surgery.
[110] Z. Oltvai,et al. Checkpoints of dueling dimers foil death wishes , 1994, Cell.
[111] Sadzuka Yasuyuki,et al. Protection against cisplatin-induced nephrotoxicity in the rat by inducers and an inhibitor of glutathione S-transferase. , 1994 .
[112] K. Matsumoto,et al. Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[113] A. Cooley,et al. Roles of cysteine conjugate beta-lyase and S-oxidase in nephrotoxicity: studies with S-(1,2-dichlorovinyl)-L-cysteine and S-(1,2-dichlorovinyl)-L-cysteine sulfoxide. , 1994, The Journal of pharmacology and experimental therapeutics.
[114] Y. Sadzuka,et al. Role of glutathione S-transferase isoenzymes in cisplatin-induced nephrotoxicity in the rat. , 1994, Toxicology letters.
[115] S. Hirota,et al. Protection against cisplatin-induced nephrotoxicity in the rat by inducers and an inhibitor of glutathione S-transferase. , 1994, Biochemical pharmacology.
[116] Gilbert Chu,et al. Massive cisplatin overdose by accidental substitution for carboplatin. Toxicity and management , 1993, Cancer.
[117] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.
[118] J. Stevens,et al. Mitochondrial HSP60 (P1 protein) and a HSP70-like protein (mortalin) are major targets for modification during S-(1,1,2,2-tetrafluoroethyl)-L-cysteine-induced nephrotoxicity. , 1993, The Journal of biological chemistry.
[119] T. Cornelison,et al. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. , 1993, Gynecologic oncology.
[120] W. Ricketts,et al. Extracellular glutathione is a source of cysteine for cells that express gamma-glutamyl transpeptidase. , 1993, Biochemistry.
[121] S. Gullans,et al. Differential actions of cisplatin on renal proximal tubule and inner medullary collecting duct cells. , 1993, The Journal of pharmacology and experimental therapeutics.
[122] S. Howell,et al. Cellular accumulation of the anticancer agent cisplatin: a review. , 1993, British Journal of Cancer.
[123] A. McGown,et al. The role of metallothionein, glutathione, glutathione S-transferases and DNA repair in resistance to platinum drugs in a series of L1210 cell lines made resistant to anticancer platinum agents. , 1993, Biochemical pharmacology.
[124] D. Crowther,et al. Glutathione S-transferase activity and isoenzyme distribution in ovarian tumour biopsies taken before or after cytotoxic chemotherapy. , 1992, British journal of cancer.
[125] H. Hollema,et al. Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy. , 1992, British Journal of Cancer.
[126] Y. Sadzuka,et al. Effect of cisplatin on the activities of enzymes which protect against lipid peroxidation. , 1992, Biochemical pharmacology.
[127] M. Raff,et al. Social controls on cell survival and cell death , 1992, Nature.
[128] A. Godwin,et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[129] M. Jones,et al. Control of the nephrotoxicity of cisplatin by clinically used sulfur-containing compounds. , 1992, Fundamental and applied toxicology : official journal of the Society of Toxicology.
[130] K. Cowan,et al. Expression of human mu or alpha class glutathione S-transferases in stably transfected human MCF-7 breast cancer cells: effect on cellular sensitivity to cytotoxic agents. , 1992, Molecular pharmacology.
[131] F. Zunino,et al. The role of glutathione in combination with cisplatin in the treatment of ovarian cancer. , 1991, Cancer treatment reviews.
[132] J. Stevens,et al. Detection of cysteine conjugate metabolite adduct formation with specific mitochondrial proteins using antibodies raised against halothane metabolite adducts. , 1991, The Journal of biological chemistry.
[133] N. Vermeulen,et al. Metabolism of L-cysteine S-conjugates and N-(trideuteroacetyl)-L-cysteine S-conjugates of four fluoroethylenes in the rat. Role of balance of deacetylation and acetylation in relation to the nephrotoxicity of mercapturic acids. , 1991, Biochemical pharmacology.
[134] B. Leyland-Jones,et al. Antineoplastic drug sensitivity of human MCF-7 breast cancer cells stably transfected with a human alpha class glutathione S-transferase gene. , 1991, Cancer research.
[135] N. Fukuishi,et al. Amelioration by ascorbic acid of cisplatin-induced injury in cultured renal epithelial cells. , 1991, Contributions to nephrology.
[136] S. Gullans,et al. Mitochondrial injury: an early event in cisplatin toxicity to renal proximal tubules. , 1990, The American journal of physiology.
[137] P. Kuchel,et al. Reaction of cis- and trans-[PtCl2(NH3)2] with reduced glutathione studied by 1H, 13C, 195Pt and 15N-{1H} DEPT NMR , 1990 .
[138] R. Puchalski,et al. Expression of recombinant glutathione S-transferase pi, Ya, or Yb1 confers resistance to alkylating agents. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[139] P. Kuchel,et al. Reaction of cis- and trans-[PtCl2(NH3)2] with reduced glutathione inside human red blood cells, studied by 1H and 15N-[1H] DEPT NMR. , 1990, Journal of inorganic biochemistry.
[140] J. Yokota,et al. Glutathione-S-transferase pi as a determinant of drug resistance in transfectant cell lines. , 1990, The Journal of biological chemistry.
[141] J. Stevens,et al. Cysteine conjugate toxicity, metabolism, and binding to macromolecules in isolated rat kidney mitochondria. , 1990, Molecular pharmacology.
[142] G. Singh. A possible cellular mechanism of cisplatin-induced nephrotoxicity. , 1989, Toxicology.
[143] T. Montine,et al. Quiescent LLC-PK1 cells as a model for cis-diamminedichloroplatinum(II) nephrotoxicity and modulation by thiol rescue agents. , 1988, Cancer research.
[144] D. J. Reed,et al. Nephrotoxicity of S-(2-chloroethyl)glutathione in the Fischer rat: evidence for gamma-glutamyltranspeptidase-independent uptake by the kidney. , 1987, The Journal of pharmacology and experimental therapeutics.
[145] Z. Siddik,et al. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. , 1987, Biochemical pharmacology.
[146] V. Gattone,et al. Mitochondrial alterations in cisplatin-induced acute renal failure. , 1986, The American journal of physiology.
[147] L. Lash,et al. Renal cysteine conjugate beta-lyase. Bioactivation of nephrotoxic cysteine S-conjugates in mitochondrial outer membrane. , 1986, The Journal of biological chemistry.
[148] L. Lash,et al. Metabolic activation and detoxication of nephrotoxic cysteine and homocysteine S-conjugates. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[149] H. Pitot,et al. Gamma-glutamyl transpeptidase--its role in hepatocarcinogenesis. , 1985, Carcinogenesis.
[150] P. Daley-Yates,et al. Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin. , 1984, Biochemical pharmacology.
[151] A. J. Gandolfi,et al. The formation and biotransformation of cysteine conjugates of halogenated ethylenes by rabbit renal tubules. , 1984, Chemico-biological interactions.
[152] E. Lock,et al. The metabolism and disposition of hexachloro-1:3-butadiene in the rat and its relevance to nephrotoxicity. , 1984, Toxicology and applied pharmacology.
[153] E. Lock,et al. Role of microsomal and cytosolic glutathione S-transferases in the conjugation of hexachloro-1:3-butadiene and its possible relevance to toxicity. , 1984, The Journal of pharmacology and experimental therapeutics.
[154] P. Bénard,et al. Whole-body autoradiographic study of the distribution of 195mPt in healthy and tumor-bearing mice treated with labeled cisplatin. , 1983, Cancer treatment reports.
[155] N. Curthoys,et al. Renal catabolism of glutathione. Characterization of a particulate rat renal dipeptidase that catalyzes the hydrolysis of cysteinylglycine. , 1982, The Journal of biological chemistry.
[156] R. Borch,et al. Effect of diethyldithiocarbamate rescue on tumor response to cis-platinum in a rat model. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[157] S. Howell,et al. Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 leukemia. , 1980, Cancer treatment reports.
[158] N. Curthoys,et al. Characterization and physiological function of rat renal gamma-glutamyltranspeptidase. , 1979, Enzyme.
[159] N. Curthoys,et al. Specificity of a particulate rat renal peptidase and its localization along with other enzymes of mercapturic acid synthesis. , 1978, Archives of biochemistry and biophysics.
[160] J. Hokanson,et al. Amelioration of cis-platinum nephrotoxicity by orgotein (superoxide dismutase). , 1978, Physiological chemistry and physics.
[161] S. Sternberg,et al. The renal pathology in clinical trials of Cis‐platinum (II) diamminedichloride , 1977, Cancer.
[162] R. Lange,et al. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). , 1973, Cancer research.
[163] R. P. Spencer,et al. The antitumor agent cis-Pt(NH 3 ) 2 Cl 2 : distribution studies and dose calculations for 193m Pt and 195m Pt. , 1973, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[164] A. Wyllie,et al. Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.
[165] A. S. Appel,et al. Acute Renal Failure , 1960, Advances in Experimental Medicine and Biology.